🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Canada / NCT05714618
Recruiting Observational

MR Evidence of Cardiac Inflammation Post-Stroke

NCT05714618 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2021-10-01
Last updated
2026-09-18

Condition(s) studied

Stroke, IschemicInflammationMyocardial Injury

Investigational drug(s) / intervention(s)

Gadolinium-enhanced cardiac MRIB Natriuretic PeptideSystemic inflammatory markers

Gadolinium-enhanced cardiac MRI: Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis.

B Natriuretic Peptide: Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days.

Systemic inflammatory markers: Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days.

Study summary

The present study is an investigator initiated, single-centre, prospective, proof-of-concept cohort study aiming to enroll 44 patients with acute middle cerebral artery (MCA) ischemic stroke, involving the right (n=22) and left (n=22) MCA territories and 24 control patients with acute focal neurological symptoms but no evidence of acute brain infarct on DWI-MRI.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: • Acute ischemic stroke in the right or left MCA territory. Acute ischemic stroke is defined as acute onset focal symptoms matching an acute brain infarct documented on Head computed tomography or diffusion-weighted imaging (DWI) MRI of the brain showing restricted diffusion. Exclusion Criteria: * History of known atrial fibrillation, prior myocardial infarction, coronary artery disease, heart failure, prior cardiovascular surgery or percutaneous intervention. * Previous stroke (occurred within 3 months before the index event) * Impaired renal function defined as a creatinine clearance \<97 mL/min in men or \<88 mL/min in women, according to the Cockcroft formula. * hs-TnT \>100 on routine acute stroke baseline bloodwork upon admission. * Clinically or neurologically unstable patients as per the treating physician. * Ongoing infection or recent infection within the previous 3 months * Surgery within 3 months before the stroke * Concurrent and active inflammatory conditions (connective tissue diseases, rheumatological disease, etc.) or use of anti-inflammatory medications * Pregnancy, Stage IV renal insufficiency, eGFR \<30, and any other contraindications to the use of gadolinium. * Stroke with symptomatic hemorrhagic transformation * Subjects will be excluded if they fail the LHSC standard MRI screening questionnaire (cardiac pacemakers/wires, aneurysm clips, shunt/surgical clips, shrapnel/bullets, dentures or metal braces, intra-uterine devices, heart valves, ear implants, prostheses, medication patches such as Nicoderm, Habitrol, or Transderm-Nitro, claustrophobia, history of a head or eye injury involving metal fragments.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Heart & Brain Lab, Western University London Ontario Recruiting

More Luciano A. Sposato trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05714618 on ClinicalTrials.gov ↗ ← All trials in Canada